Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
45.57
+1.30 (2.94%)
At close: May 12, 2025, 4:00 PM
45.57
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Mirum Pharmaceuticals stock have an average target of 60.8, with a low estimate of 39 and a high estimate of 76. The average target predicts an increase of 33.42% from the current stock price of 45.57.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 | 3 |
Buy | 8 | 8 | 7 | 7 | 7 | 7 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 13 | 11 | 11 | 11 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JMP Securities | JMP Securities | Buy Maintains $74 → $76 | Buy | Maintains | $74 → $76 | +66.78% | May 9, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $66 → $72 | Strong Buy | Maintains | $66 → $72 | +58.00% | Feb 28, 2025 |
Baird | Baird | Buy Maintains $50 → $55 | Buy | Maintains | $50 → $55 | +20.69% | Feb 27, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $74 | Buy | Reiterates | $74 | +62.39% | Feb 24, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +44.83% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
436.32M
from 336.89M
Increased by 29.51%
Revenue Next Year
524.75M
from 436.32M
Increased by 20.27%
EPS This Year
-0.96
from -1.85
EPS Next Year
-0.34
from -0.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 461.9M | 596.3M | 782.8M | ||
Avg | 436.3M | 524.8M | 638.1M | ||
Low | 403.0M | 440.7M | 540.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 37.1% | 36.7% | 49.2% | ||
Avg | 29.5% | 20.3% | 21.6% | ||
Low | 19.6% | 1.0% | 3.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.01 | 0.32 | 1.46 | ||
Avg | -0.96 | -0.34 | 0.78 | ||
Low | -1.47 | -1.59 | -0.23 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.